GENEDIT TEAMS WITH WESTWOOD & WILSHIRE TO BRING IN FIRST VICE PRESIDENT OF CHEMISTRY

South San Francisco, CA, May 24—GenEdit, a Series A gene editing biotech, has hired Yvonne Angell as the new Vice President of Chemistry. The discovery stage company is exploring multiple therapeutic indications for its technologies in non-viral delivery of CRISPR/ Cas-9 gene editing.

Dr. Angell joins GenEdit from ChemPartner, where she has been the Head of Peptide Chemistry and Peptide Operations since 2015. In her role there, as well as at previous roles at Ipsen, Affymax, and Weyth, Dr. Angell worked across modalities and indication to lead chemistry teams in discovering solutions. She received her PhD in Medicinal Chemistry from the University of Wisconsin. She is the inventor of five patents, has over fifteen publications, and is a distinguished speaker.

The search was successfully led by James Reynolds for Westwood & Wilshire’s Life Sciences Practice.

Westwood & Wilshire is a retained executive search firm that recognizes people as any organization’s top asset. The firm has delivered premier talent to many of the world’s most innovative companies in life sciences, healthcare, and advanced technology. Westwood & Wilshire specializes in bringing top-tier candidates at the mid-management to C-Suite level to clients ranging from VC backed start-ups to mid-sized commercial entities. The firm has offices in Los Angeles, Silicon Valley, Scottsdale, and Connecticut serving clients worldwide.